• ̍̍ CSE: BRAX
  • ̍̍ OTC: BRAXF
  • ̍̍ FWB: 4960

News Releases

October 29, 2021

Voting Results from the Annual General Meeting

Braxia Scientific Announces Voting Results from the Annual General Meeting of Shareholders   TORONTO, ONTARIO October 29, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce the voting results from its Annual General Meeting of Shareholders held on Thursday, October 28, 2021. A total of 11.77% of the issued and outstanding common shares of the Company were represented either in person or by proxy at the meeting. The following 4 nominees proposed by the Company were elected as Directors of Braxia Scientific to serve until the Company’s next Annual Meeting of Shareholders or until their successors are elected or appointed, with shares represented at the meeting voting in favor of individual nominees as follows:...

October 22, 2021

Braxia Scientific Featured in National News; W5

Braxia Scientific Featured in National News, W5 Canada’s Most-Watched Documentary Series, Providing Access and Promoting Use of Ketamine to Treat Brain-Based Illnesses TORONTO, ONTARIO October 22, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its inclusion in recent national and local news coverage of psychedelics to treat mental disorders. Braxia Scientific CEO Dr. Roger McIntyre will be featured on CTV’s W5, Canada’s most-watched current affairs and documentary program. The episode, entitled “Psychedelic Healing,” will air on Saturday, October 23, 2021, at 7 p.m. Eastern Standard Time (EST). Braxia Scientific and the Canadian Rapid Treatment Center of Excellence (CRTCE), a wholly owned subsidiary, are also highlighted in a recent article by Toronto Life, a monthly...

October 21, 2021

Journal of the Royal Society of Medicine

Journal of the Royal Society of Medicine Publishes New COVID-19 Suicide Research Led by Braxia Scientific CEO Dr. Roger McIntyre Journal of the Royal Society of Medicine Publishes New COVID-19 Suicide Research Led by Braxia Scientific CEO Dr. Roger McIntyre Findings Underscore Company Core Objectives to Develop Ketamine Derivatives as Additional Measures to Further Reduce Suicidality TORONTO, ONTARIO October 21, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce the publication of a new study led by Braxia Scientific CEO Dr. Roger McIntyre in the Journal of the Royal Society of Medicine. The publication, entitled “Suicide reduction in Canada during the COVID-19 pandemic: lessons informing national prevention strategies for suicide reduction” was initiated to evaluate...

October 14, 2021

NBA Champion Lamar Odom

Braxia Scientific CEO Dr. Roger McIntyre to Share Stage With NBA Champion Lamar Odom and ‘Psychedelic Concierge’ Zappy Zapolin to Discuss the Benefits of Ketamine Treatment for Mental Health Panel discussion on November 9 at Wonderland: Miami will review the benefits of ketamine treatment for depression and other mental health conditions TORONTO, ONTARIO October 14, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its CEO, Dr. Roger McIntyre, will join fellow VIPs Lamar Odom and Zappy Zapolin for a panel discussion entitled “Ketamine Treatment Goes Mainstream” at the Wonderland: Miami conference on November 9, 2021. The two-day event, which is scheduled to begin November 8 at the Adrienne Arsht Center for the Performing...

September 30, 2021

Encouraging Results of Ketamine Study

Braxia Scientific Reports Encouraging Results of Ketamine Study Showing Significant Reduction in Depressive Symptoms and Suicidality with Ketamine as a Solo Treatment TORONTO, ONTARIO Sept. 30, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to report encouraging preliminary findings of a recent clinical study that suggests ketamine may be as effective as a standalone antidepressant, versus as an adjunctive therapy. The study, which was conducted at the Canadian Rapid Treatment Centre of Excellence (CRTCE), a wholly owned Braxia subsidiary, showed comparable clinical benefits (e.g., antidepressant effects and reduction in suicidal thoughts) in a large sample of 220 patients with treatment-resistant depression (TRD) who received intravenous (IV) ketamine infusions as a monotherapy, as compared with those receiving...

September 23, 2021

Canaccord Genuity

Canaccord Genuity 41st Annual Growth Conference Registration for Canaccord Genuity 41st Annual Growth Conference Click here Symbols – CSE: BRAX  OTC: BRAXF  FWB: 496

September 23, 2021

Global Investment Conference

H.C. Wainwright 23rd Annual Global Investment Conference – September 13-15, 2021 Registration for H.C. Wainwright 23rd Annual Global Investment Conference – September 13-15, 2021 Click here Symbols – CSE: BRAX  OTC: BRAXF  FWB: 496

August 30, 2021

First Quarter 2022 Financial Results

Braxia Scientific Reports First Quarter 2022 Financial Results; Company Achieves 80% Revenue Growth from Expanding Clinic Patient Base Revenue from four Canadian clinics increased 80.3% to $407,075 year-over-year Exceeding monthly IV Ketamine infusion targets, ramping up infusions at new Montreal clinic Advancing three funded clinical trials through Braxia Scientific’s network of clinics, including a Ketamine trial for Bipolar Depression, a Ketamine trial to rapidly reduce suicidality, and the first multiple-dose psilocybin trial to combat treatment-resistant depression TORONTO, ONTARIO Aug. 30, 2021 – Braxia Scientific Corp. (“Braxia Scientific,” or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, today announced the filing of its fiscal first-quarter results for the three-month period ending June 30, 2021. Complete financial statements along with related management discussion and analysis can be...

August 27, 2021

Landmark Clinical Trial

BRAXIA SCIENTIFIC ANNOUNCES PARTICIPATION AT CANACCORD GENUITY 2021 ANNUAL GROWTH CONFERENCE AUGUST 10-12 TORONTO, ONTARIO Aug. 6, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the upcoming Canaccord Genuity Annual Growth Conference. The conference will be held virtually on August 10-12, 2021. Braxia Scientific CEO Dr. Roger McIntyre will deliver a presentation on the company’s initiatives related to developing novel therapeutics and delivery systems for treating depression and other brain-based disorders, as well as its administration of patient care in its network of clinics. Presentation Details: Date: Tuesday, August 10, 2021 Time: 11:30 a.m. ET Event Registration: https://bit.ly/3josIt3 For additional information on the conference, please CLICK HERE. About Braxia Scientific Corp. Braxia Scientific is a...

August 6, 2021

CANACCORD GENUITY 2021 ANNUAL GROWTH CONFERENCE

BRAXIA SCIENTIFIC ANNOUNCES PARTICIPATION AT CANACCORD GENUITY 2021 ANNUAL GROWTH CONFERENCE AUGUST 10-12 TORONTO, ONTARIO Aug. 6, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the upcoming Canaccord Genuity Annual Growth Conference. The conference will be held virtually on August 10-12, 2021. Braxia Scientific CEO Dr. Roger McIntyre will deliver a presentation on the company’s initiatives related to developing novel therapeutics and delivery systems for treating depression and other brain-based disorders, as well as its administration of patient care in its network of clinics. Presentation Details: Date: Tuesday, August 10, 2021 Time: 11:30 a.m. ET Event Registration: https://bit.ly/3josIt3 For additional information on the conference, please CLICK HERE. About Braxia Scientific Corp. Braxia Scientific is a...

July 30, 2021

CORPORATE UPDATE AND REPORTING

BRAXIA SCIENTIFIC PROVIDES CORPORATE UPDATE AND REPORTS FISCAL FOURTH QUARTER AND FULL-YEAR 2021 FINANCIAL RESULTS TORONTO, ONTARIO July 30, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), today announced the filing of its fiscal fourth-quarter and year-end results for the three- and 12-month periods ending March 31, 2021. Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval (SEDAR), the electronic filing system for the disclosure documents of issuers across Canada at www.SEDAR.com. Through its global leading researchers and experienced implementation team, Braxia Scientific has established its presence in the mental health industry. Braxia Scientific successfully expanded its network of multidisciplinary clinics to four in 2021, with one of very few private clinics approved in Canada to provide innovative intravenous (IV) Ketamine treatments to...

July 7, 2021

EXPERIMENTAL MEDICINE IN PSYCHIATRY

BRAXIA SCIENTIFIC TO DISCUSS PSYCHIATRIC TREATMENT DISCOVERY AND DEVELOPMENT WITH OXFORD UNIVERSITY RESEARCHERS AT AIMDAY EXPERIMENTAL MEDICINE IN PSYCHIATRY ON JULY 7, 2021 TORONTO, ONTARIO July 7, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research and development company along with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the upcoming Academic Industry Meeting Day (AIMday) on “Experimental Medicine in Psychiatry,” hosted by Oxford University on Wednesday, July 7, 2021. Braxia CEO Dr. Roger McIntyre will engage with Oxford scientists on the question of “How can we advance treatment discovery and development in psychiatry targeting cognition?” They will describe how research will be conducted with ketamine and psychedelics that integrates machine-learning, proof-of-mechanism research and implementation science which will be critical for the...